Anti-coagulation factor XI antibodies
View Patent ↗Antibodies that bind the apple 2 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa are described.
1. An antibody or antigen binding fragment comprising:
a heavy chain (HC) variable domain comprising
an HC complementarity determining region (HC CDR) 1 having the amino acid sequence set forth in SEQ ID NO:7, an HC CDR 2 having the amino acid sequence set forth in SEQ ID NO:8, and an HC CDR 3 having the amino acid sequence set forth in SEQ ID NO:9 or 13 and
a light chain (LC) variable domain comprising an LC CDR 1 having the amino acid sequence set forth in SEQ ID NO:10, an LC CDR 2 having the amino acid sequence set forth in SEQ ID NO:11, and an LC CDR 3 having the amino acid sequence set forth in SEQ ID NO:12; and,
wherein the antibody or antigen binding fragment binds the apple 2 domain of coagulation factor XI (FXI) and inhibits activation of FXI.
2. The antibody or antigen binding fragment of claim 1 , wherein the antibody or antigen binding fragment comprises:
an HC variable domain having the amino acid sequence shown in SEQ ID NO:24 or 20 and an LC variable domain having amino acid sequence shown in SEQ ID NO:21.
3. The antibody or antigen binding fragment of claim 1 , which is an antibody, wherein the antibody comprises an HC constant domain having the amino acid sequence shown in SEQ ID NO:14 or 40 or variant thereof in which the constant domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof.
4. The antibody or antigen binding fragment of claim 1 , which is an antibody, wherein the antibody comprises an LC constant domain comprising the amino acid sequence shown in SEQ ID NO:15 or variant thereof in which the constant domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof.
5. The antibody or antigen binding fragment of claim 1 , which is an antibody wherein the antibody comprises a heavy chain constant domain of the human IgG1, IgG2, IgG3, or IgG4 isotype or variant thereof in which the constant domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof.
6. The antibody or antigen binding fragment of claim 1 , which is an antibody wherein the antibody comprises a heavy chain constant domain of the human IgG4 isotype or variant thereof in which the constant domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof.
7. The antibody or antigen binding fragment of claim 1 , which is an antibody wherein the antibody comprises a heavy chain having the amino acid sequence shown in SEQ ID NO:22, 25, 27, 28, 33, 34, 35, or 36; and a light chain having the amino acid sequence shown in SEQ ID NO:23.
8. A composition comprising an antibody or antigen binding fragment of claim 1 and a pharmaceutically acceptable carrier or diluent.
9. A method of treating a thromboembolic disorder or disease in a subject comprising:
administering to a subject in need thereof a therapeutically effective amount of the antibody or antigen binding fragment of any one of claims 1 - 7 .
10. The method of claim 9 , wherein the subject in need of treatment is a subject suffering from or at risk of suffering from myocardial infarction, ischemic stroke, pulmonary thromboembolism, venous thromboembolism (VTE), atrial fibrillation, disseminated intravascular coagulation, medical device-related thromboembolic disorders, severe systemic inflammatory response syndrome, metastatic cancer, or an infectious disease.
11. The method of claim 9 , wherein the subject in need of treatment is a subject with pathological activation of FXI.
12. The method of claim 9 wherein the therapeutically effective amount of the antibody or antigen binding fragment comprises about 0.3 to about 3.0 mg of the antibody or antigen binding fragment/kg of the subject.
13. The method of claim 12 , wherein the therapeutically effective amount of the antibody or antigen binding fragment comprises about 1.0 to 2.0 mg of the antibody or antigen binding fragment/kg of the subject.
14. An antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO:25 or 28 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO:23.
15. The antibody of claim 14 , wherein the heavy chain consists of the amino acid sequence set forth in SEQ ID NO:25.
16. A composition comprising the antibody of claim 14 and a pharmaceutically acceptable carrier.
17. A method of treating a thromboembolic disorder or disease in a subject comprising:
administering to a subject in need thereof a therapeutically effective amount of the antibody or antigen binding fragment of claim 14 .
18. The method of claim 17 , wherein the subject in need of treatment is a subject suffering from or at risk of suffering from myocardial infarction, ischemic stroke, pulmonary thromboembolism, venous thromboembolism (VTE), atrial fibrillation, disseminated intravascular coagulation, medical device-related thromboembolic disorders, severe systemic inflammatory response syndrome, metastatic cancer, or an infectious disease.